


|  |   |   |   |
|--|---|---|---|
| <b>NAME</b>  | Dr. Dibyakanti Mandal                     |   |  |
| <b>DESIGNATION</b>   | Assistant Professor III                   |   |   |
| <b>EMAIL ID</b>  | dmandal1@amity.edu                        |   |   |
| <b>CONTACT NUMBER</b>  | 8584000652                                |   |   |
| <b>RESEARCH INTERESTS</b>  | Virology/Infectious Diseases/Gene Therapy |   |   |
| <b>EDUCATIONAL QUALIFICATIONS:</b>   |   |   |   |
| Name of College / University   | Degree                                    | Year  |   |
| Calcutta University  | B.Sc. (Chemistry Hons)                    | 1993  |   |
| Calcutta University  | M.Sc. (Biochemistry)                      | 1995  |   |
| Calcutta University  | Ph.D. (Biochemistry)                      | 2003  |   |
| <b>Title of Ph.D. thesis: Genomic Characterization of Human Immunodeficiency virus Type-1 Circulating in Eastern and Northeastern Regions of India</b> |   |   |   |
| <b>EXPERIENCE (in chronological order): Total 20 Years Research &amp; Teaching</b>   |   |   |   |
| Designation  | Type of post held (teaching/ research)    | Name of the Institute   | Year (From – To)  |
| Associate Professor  | Teaching/Research                         | PDM University  | 2021-2022   |
| Assistant Professor  | Teaching/Research                         | PDM University  | 2019-2021   |
| Sr. Program Officer  | Research/Administration                   | INCLIN Trust International  | 2017-2018   |
| Sr. Program Officer  | Research                                  | THSTI   | 2016-2017   |
| Scientist B  | Research                                  | AIIMS, New Delhi  | 2015-2016   |
| Research Scientist   | Research                                  | University of Iowa, USA   | 2011-2013   |
| Postdoctoral Scientist   | Research                                  | University of Iowa, USA   | 2006-2011   |
| Postdoctoral Scientist   | Research                                  | Albert Einstein College of Medicine, NY, USA  | 2002-2006   |
| <b>No. of Ph.D. students supervised</b>  |   |   |   |
| <b>No. of Post-Doc</b>   |   |   |   |
| <b>No. of M.Tech. Students supervised:</b>   |   |   |   |
| <b>No. of B.Tech. Students supervised:</b>   |   |   |   |
| <b>PUBLICATIONS</b><br>(mention total no. here): 19  |   | <ul style="list-style-type: none"> <li>• Apita Adhikari , <b>Dibyakanti Mandal</b> , Jyotishka Nath ,Sriparna De , Dipak Rana, Dipankar Chattopadhyay . June 2022. COVID-19 mitigation: Nanotechnological intervention, perspective, and future scope. (Accepted in Materials Advances; Royal Society of Chemistry).</li> <li>• <b>Dibyakanti Mandal*</b>, <b>D. Pandey</b>, <b>Debi P Sarkar</b> and <b>Manish Kumar</b>. 2022. Remdesivir, Zidovudine (AZT) and Nevirapine inhibit Chandipura virus through high energy interactions with the RdRp domain of the polymerase protein L.</li> </ul> |   |

BioRxiv.doi: <https://doi.org/10.1101/2022.03.02.482698>. ( as Corresponding author).

- **Dibyakanti Mandal\***, Desai D, Sinha S. **2021**. High prevalence of plasma EBV among the HIV positive individuals, with or without malignancies, attending the clinic at AIIMS, New Delhi. (Accepted in *VirusDisease* ; \*corresponding author).
- **\*Dibyakanti Mandal. 2020**. Coronavirus threat to Indian population : risk factors, transmission dynamics and preparedness to prevent the spread of the virus. *VirusDiseases*. April 20; 1-4.
- **Dibyakanti Mandal\***. 2019. Association of vitamin D and VDR in leprosy disease progression : implication of new strategies for treatment and clinical management (\*As corresponding author, Invited book chapter in '*Leprosy: from diagnosis to treatment*', Nova Publisher, New York, USA).
- Sinha S, Agarwal A, Gupta K, **Mandal D**, Jain M, Detels R, Nandy K, DeVos MA, Sharma SK, Manoharan N, Julka PK, Rath GK, Ambinder RF, Mitsuyasu RT. **2018**. Prevalence of HIV in patients with malignancy and of malignancy in HIV patients in a tertiary care center from North India. *Curr HIV Res*. 2018 Oct 18.
- Sinha S, Gupta K, Nawaid Khan, **Mandal D**, *et al.* **2018**. Higher frequency of HIV-1 drug resistance and increased NRTI mutations among the HIV-1 positive ART naive individuals co-infected with Mycobacterium Tuberculosis compared to only HIV infection in India. *Infectious Disease: Research and Treatment*.
- [Sinha S](#), [Gupta K](#), [Mandal D](#), [Das BK](#), [Pandey RM](#). **2018**. Serum and Bronchoalveolar Lavage Fluid 25(OH) Vitamin D3 Levels in HIV-1 and Tuberculosis: A Cross-Sectional Study from a Tertiary Care Center in North India. *Curr HIV Res*. 27.
- **Mandal D\***, Reja AH, Biswas N, Bhattacharya P, Patra P, Bhattacharya B. **2015**. Vitamin D receptor expression levels determine the severity and complexity of disease progression among leprosy reaction patients. *New Microbes and New Infections*. July, Vol 6: 35-39. (\* As corresponding author).
- **Mandal D**, Feng Z, Stoltzfus CM. **2010**. Excessive Human Immunodeficiency Virus Type-1 RNA splicing and inhibition of virus replication induced by modified U1 snRNAs *Journal of Virology*: December **2010**, Vol. 84, No. 24, p. 12790-12800.
- **Mandal D**, Exline C, Feng Z and Stoltzfus CM. **2009**. Regulation of *vif* mRNA splicing by human

|  |  |
|--|--|
|  | <p>immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G. <i>Journal of Virology</i>. Jun. 83(12): 6067-78.</p> <ul style="list-style-type: none"> <li>• <b>Mandal, D</b>, Feng Z and Stoltzfus CM. <b>2008</b>. Gag-Processing defect of human immunodeficiency virus type 1 integrase E246 and G247 mutants is caused by activation of an overlapping 5' splice site. <i>Journal of Virology</i>. Feb. 82(3): 1600-1604.</li> <li>• <b>Mandal D</b>, Das C, Le Grice S, Prasad VR. <b>2006</b>. Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function. <i>Nucleic Acids Research</i>. 34 (10): 2853-2863.</li> <li>• Bhattacharya B, Karak K, Ghosal A, Roy A, Das S, Dandapat P, Khetawat D, <b>Mandal D</b>, Bhattacharya S and Chakrabarti S. <b>2003</b>. Development of a new sensitive and efficient multiplex polymerase chain reaction (PCR) for identification and differentiation of different mycobacterial species. <i>Trop Med Int Health</i>. Feb; 8(2):150-7.</li> <li>• Bhanja P, <b>Mandal D</b>, Jana S, Bhattacharya SK and Chakrabarti S. <b>2004</b>. Detection and characterization of HIV type 2 in Calcutta, India. <i>AIDS Res Hum Retroviruses</i>. Jan; 20(1):101-4.</li> <li>• <b>Mandal D</b>, Jana S, Bhattacharya S, Bhattacharya SK and Chakrabarti S. <b>2002</b>. HIV-1 type-1 subtypes circulating in eastern and north-eastern regions of India. <i>AIDS Res Hum Retroviruses</i>. Nov; 18(16):1219-27.</li> <li>• Saha S, <b>Mandal D</b>, Khetawat D, Roy A, Chakrabarti S and Bhattacharya B. 2002. A molecular approach (multiplex polymerase chain reaction) for diagnosis of rhinosporidiosis. <i>Indian Journal of Otolaryngology and Head &amp; Neck Surgery</i>. Oct; 54 (4): 264-67.</li> <li>• <b>Mandal D</b>, Jana S, Panda S, Bhattacharya S, Ghosh TC, Bhattacharya SK and Chakrabarti S. <b>2000</b>. Distribution of HIV-1 subtypes in female sex workers of Calcutta, India. <i>Ind. J. Med. Res</i>. 112: 165 -172.</li> <li>• <b>Mandal D</b> and Prasad VR. <b>2009</b>. Analysis of 2-LTR circle junctions of viral DNA in infected cell. <i>Methods in Molecular Biology</i>. 485: 73-85.</li> </ul> |
| <b>PATENTS</b> ( <i>total no.</i> )  | <i>Details:</i>  |
| <b>RESEARCH PROJECTS</b><br>Completed: ( <i>total no.</i> ) : 2<br>Ongoing: ( <i>total no.</i> ) | <i>Details:</i><br><b>1. Effects of unspliced RNA levels in HIV-1 Gag Assembly</b><br><b>2. Immune Response against HIV-1 subtype C envelope Proteins expressed by recombinant vaccinia virus</b>  |

|   |  |
|---|--|
| <p><b>AWARDS &amp; HONOURS/<br/>DISTINCTIONS</b></p>            | <p><b>Details:</b><br/> 1996: <b>Junior research fellowship</b> awarded by Department of Biotechnology, Govt. of India.<br/> 2001: <b>Senior research fellowship</b> awarded by Council of Scientific and Industrial research (CSIR), India.<br/> 2001: <b>UNESCO-IUMS-MIRSENS-SGM</b> international fellowship (UNESCO). From<br/> 2008: <b>Levitt center pilot grant</b> obtained from University of Iowa, Project title: ‘Effects of unspliced RNA levels on HIV-1 Gag assembly’.<br/> 2020 : <b>Editorial Board member</b>, <i>International Journal of Infectious Diseases and Therapy</i> (Science publishing group).<br/> 2020: <b>Invited Reviewer</b>, VirusDiseases (Springer).<br/> 2022: Awdred <b>ECCMID outreach grant</b> (Travel award) for 2022 meeting at Lisbon, Portugal<br/> 2022: Reviewer Board Member, Archieves of Advanced Biomedical Research, Infact Publications, USA<br/> 2022 : Reviewer Board Member, Annals of Pharmacology, Infact publications, USA</p> |
| <p><b>MEMBERSHIP</b> with Professional/<br/>Academic bodies</p> | <p><b>Details:</b><br/> <i>Former member, New York Academy of Sciences, New York, USA</i></p>  |